This interdisciplinary program project grant involves four highly collaborative projects and three Core elements involving faculty from five departments of the Schools of Pharmacy and Medicine of the University of Washington and collaboration with two other institutions. Collectively, it is focused (i) on understanding molecular mechanisms that complicate prediction of drug-drug interactions from in vitro data, and (ii) developing methods to allow the prediction of such events from in vitro experiments before humans are exposed to dangerous combinations of drugs in vivo. Project 1 will define the influence of genotype on the magnitude of inhibitory and inductive drug-drug interactions involving the oral anticoagulant drug, warfarin. This information can guide management of warfarin drug interactions in carriers of common polymorphisms within genes controlling the pharmacokinetics and pharmacodynamics of the drug. Interactions involving alkylamine drugs are often complicated by time-dependent inhibition of P450s through formation of a metabolite-intermediate (Ml) complex. Project 2 is pioneering the concept that formation of secondary hydroxylamine metabolites of alkylamine drugs are the pivotal step in Ml complex formation in vitro and in vivo. Extrapolating from in vitro kinetic data to the in vivo situation is further complicated by the phenomenon of P450 allosterism. Project 3 is studying the mechanistic underpinning for activation kinetics among human P450s and will also test if such allosteric behavior occurs in vivo. Finally, Project 4 addresses the quantitative prediction of P-glycoprotein based drug-drug interactions at the human blood-brain barrier These studies are possible because of novel and innovative imaging methodologies developed by this project that will be used combination with cell model systems and rodent studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM032165-28
Application #
7919268
Study Section
Special Emphasis Panel (ZGM1-PPBC-6 (PH))
Program Officer
Okita, Richard T
Project Start
1997-08-01
Project End
2013-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
28
Fiscal Year
2010
Total Cost
$1,395,460
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379
Shirasaka, Y; Chaudhry, A S; McDonald, M et al. (2016) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 16:375-87
Manoj, Kelath Murali; Parashar, Abhinav; Gade, Sudeep K et al. (2016) Functioning of Microsomal Cytochrome P450s: Murburn Concept Explains the Metabolism of Xenobiotics in Hepatocytes. Front Pharmacol 7:161
Stamper, Brendan D; Garcia, Michael L; Nguyen, Duy Q et al. (2015) p53 Contributes to Differentiating Gene Expression Following Exposure to Acetaminophen and Its Less Hepatotoxic Regioisomer Both In Vitro and In Vivo. Gene Regul Syst Bio 9:1-14
McDonald, Matthew G; Au, Nicholas T; Rettie, Allan E (2015) P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms. Drug Metab Dispos 43:1661-9
Chaudhry, Amarjit S; Prasad, Bhagwat; Shirasaka, Yoshiyuki et al. (2015) The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos 43:1226-35
Liu, Li; Collier, Ann C; Link, Jeanne M et al. (2015) Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. Drug Metab Dispos 43:1795-804
Ho, Han Kiat; Chan, James Chun Yip; Hardy, Klarissa D et al. (2015) Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metab Rev 47:21-8
Chapron, Brian; Risler, Linda; Phillips, Brian et al. (2015) Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes. J Pharm Pharm Sci 18:101-11
Sager, J E; Lutz, J D; Foti, R S et al. (2014) Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther 95:653-62

Showing the most recent 10 out of 361 publications